- Home
- TVGN vs GOSS Comparison
TVGN vs GOSS Comparison
Compare TVGN & GOSS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TVGN
- GOSS
- Stock Information
- Founded
- TVGN 2020
- GOSS 2015
- Country
- TVGN United States
- GOSS United States
- Employees
- TVGN N/A
- GOSS N/A
- Industry
- TVGN Blank Checks
- GOSS Biotechnology: Pharmaceutical Preparations
- Sector
- TVGN Finance
- GOSS Health Care
- Exchange
- TVGN Nasdaq
- GOSS Nasdaq
- Market Cap
- TVGN 198.6M
- GOSS 188.6M
- IPO Year
- TVGN N/A
- GOSS 2019
- Fundamental
- Price
- TVGN $0.98
- GOSS $0.84
- Analyst Decision
- TVGN Strong Buy
- GOSS Strong Buy
- Analyst Count
- TVGN 1
- GOSS 4
- Target Price
- TVGN $10.00
- GOSS $7.50
- AVG Volume (30 Days)
- TVGN 528.6K
- GOSS 1.5M
- Earning Date
- TVGN 05-28-2025
- GOSS 05-06-2025
- Dividend Yield
- TVGN N/A
- GOSS N/A
- EPS Growth
- TVGN N/A
- GOSS N/A
- EPS
- TVGN N/A
- GOSS N/A
- Revenue
- TVGN N/A
- GOSS $114,701,000.00
- Revenue This Year
- TVGN N/A
- GOSS N/A
- Revenue Next Year
- TVGN N/A
- GOSS $172.31
- P/E Ratio
- TVGN N/A
- GOSS N/A
- Revenue Growth
- TVGN N/A
- GOSS N/A
- 52 Week Low
- TVGN $0.26
- GOSS $0.50
- 52 Week High
- TVGN $3.09
- GOSS $1.55
- Technical
- Relative Strength Index (RSI)
- TVGN 40.84
- GOSS 37.58
- Support Level
- TVGN $0.93
- GOSS $0.80
- Resistance Level
- TVGN $1.13
- GOSS $0.88
- Average True Range (ATR)
- TVGN 0.11
- GOSS 0.10
- MACD
- TVGN 0.00
- GOSS -0.01
- Stochastic Oscillator
- TVGN 25.00
- GOSS 20.24
About TVGN Tevogen Bio Holdings Inc. Common Stock
Tevogen Bio Holdings Inc a clinical-stage specialty immunotherapy company harnessing CD8+ cytotoxic T lymphocytes (CD8+ CTLs or CTLs), to develop off-the-shelf, precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders.
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.